Vir Biotechnology EVP logs 16,817-share stock sale

Vir Biotechnology, Inc. executive Vanina de Verneuil, EVP, General Counsel and Corporate Secretary, reported two open-market sales of common stock.

Accepted by SEC EDGAR 02/26/2026 - 04:54 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology, Inc. executive Vanina de Verneuil, EVP, General Counsel and Corporate Secretary, reported two open-market sales of common stock. She sold 13,700 shares on February 25, 2026 at $9.82 per share and 3,117 shares on February 24, 2026 at $9.5326 per share.

The 13,700-share sale was an automatic, mandatory transaction under Rule 10b5-1 to cover tax withholding on vesting restricted stock units and was not a discretionary trade. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 2, 2025, and she held 112,982 shares directly after the last reported sale.

Insider Trade Summary

Net Seller: 16,817 shares

Net Sell 2 txns

Insider de Verneuil Vanina

Role EVP, General Counsel, Corp Sec

Sold 16,817 shs ($164K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,700	$9.82	$135K
Sale	Common Stock	3,117	$9.5326	$30K

Holdings After Transaction: Common Stock — 112,982 shares (Direct)

Footnotes (2)

1. F1. Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vir Biotechnology (VIR) executive Vanina de Verneuil report in this Form 4?

Vanina de Verneuil reported selling a total of 16,817 shares of Vir Biotechnology common stock in two transactions. These included 13,700 shares at $9.82 and 3,117 shares at $9.5326, all as open-market sales under a Rule 10b5-1 trading plan.

How many Vir Biotechnology (VIR) shares did Vanina de Verneuil sell and at what prices?

She sold 13,700 Vir Biotechnology common shares at $9.82 per share on February 25, 2026, and 3,117 shares at $9.5326 per share on February 24, 2026. Together, these Form 4 transactions totaled 16,817 shares of common stock sold.

Were Vanina de Verneuil’s Vir Biotechnology (VIR) stock sales discretionary trades?

The 13,700-share sale was an automatic, mandatory sale to satisfy Vir Biotechnology’s tax withholding obligations on vesting restricted stock units, not a discretionary trade. Both reported sales were executed under a Rule 10b5-1 trading plan adopted on June 2, 2025.

What is the purpose of the automatic 13,700-share sale reported for Vir Biotechnology (VIR)?

The automatic 13,700-share sale was conducted under a Rule 10b5-1 arrangement to satisfy Vir Biotechnology’s tax withholding obligations related to vesting restricted stock units. According to the filing, this sale was automatic and mandatory rather than a discretionary stock sale by the executive.

What role does Vanina de Verneuil hold at Vir Biotechnology (VIR)?

Vanina de Verneuil serves as Executive Vice President, General Counsel and Corporate Secretary at Vir Biotechnology. Her Form 4 filing reflects stock transactions in this capacity, including open-market sales of common stock executed under a pre-established Rule 10b5-1 trading plan.

How many Vir Biotechnology (VIR) shares did Vanina de Verneuil hold after these transactions?

After the last reported transaction on February 25, 2026, Vanina de Verneuil directly held 112,982 shares of Vir Biotechnology common stock. This share balance is stated in the Form 4 as the total number of shares owned following the final reported sale.

What is a Rule 10b5-1 trading plan in the context of Vir Biotechnology (VIR)?

A Rule 10b5-1 trading plan allows insiders to prearrange stock transactions according to set instructions. In this case, Vanina de Verneuil’s reported Vir Biotechnology stock sales were carried out under such a plan adopted on June 2, 2025, providing structured, preplanned trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de Verneuil Vanina

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel, Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		S(1)		3,117	D	$9.5326	126,682	D
Common Stock	02/25/2026		S(2)		13,700	D	$9.82	112,982	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2025.

Remarks:

	/s/ Lorin Wagner, Attorney-In-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.